FDA Flags Off-Target Effects of Vertex, CRISPR’s Sickle Cell Therapy Ahead of Adcomm

Ahead of a Tuesday advisory committee meeting, FDA staff have called into question the safety risk testing for Vertex Pharmaceuticals and CRISPR Therapeutics’ investigational sickle cell disease therapy exagamglogene autotemcel (exa-cel).